XNASKZR
Market cap46mUSD
Dec 23, Last price
6.44USD
1D
0.94%
1Q
1,066.67%
IPO
-63.80%
Name
Kezar Life Sciences Inc
Chart & Performance
P/E
—
P/S
6.71
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
47.86%
Rev. gr., 5y
%
Revenues
7m
Net income
-102m
L+55.96%
CFO
-82m
L+38.74%
Earnings
Mar 12, 2025
Profile
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 7,000 | |||||||
Cost of revenue | 113,303 | 72,185 | 56,169 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (106,303) | (72,185) | (56,169) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (2,923) | (1,351) | ||||||
Tax Rate | ||||||||
NOPAT | (106,303) | (69,262) | (54,818) | |||||
Net income | (101,870) 55.96% | (65,316) 22.59% | (53,279) 36.65% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 638 | 127,861 | 103,054 | |||||
BB yield | -0.93% | -26.96% | -11.68% | |||||
| Debt | ||||||||
Debt current | 6,024 | 2,565 | 1,199 | |||||
Long-term debt | 24,785 | 30,129 | 17,267 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (170,563) | (243,867) | (189,889) | |||||
| Cash flow | ||||||||
Cash from operating activities | (81,645) | (58,846) | (42,437) | |||||
CAPEX | (1,810) | (1,578) | (316) | |||||
Cash from investing activities | 76,046 | (91,392) | (28,444) | |||||
Cash from financing activities | 638 | 127,861 | 112,585 | |||||
FCF | (101,821) | (76,437) | (54,066) | |||||
| Balance | ||||||||
Cash | 201,372 | 276,561 | 208,355 | |||||
Long term investments | ||||||||
Excess cash | 201,022 | 276,561 | 208,355 | |||||
Stockholders' equity | (350,820) | (249,748) | (180,889) | |||||
Invested Capital | 560,335 | 540,884 | 391,809 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 72,554 | 67,369 | 52,759 | |||||
Price | 0.95 -86.54% | 7.04 -57.89% | 16.72 220.31% | |||||
Market cap | 68,737 -85.51% | 474,277 -46.24% | 882,136 284.04% | |||||
EV | (101,826) | 230,410 | 692,247 | |||||
EBITDA | (105,237) | (71,162) | (54,659) | |||||
EV/EBITDA | 0.97 | |||||||
Interest | 1,550 | 1,185 | 159 | |||||
Interest/NOPBT | ||||||||